scholarly journals Management of Anterior Chamber Dislocation of a Fluocinolone Acetonide Implant: A Case Report

2020 ◽  
pp. 1-4
Author(s):  
Clara Monferrer Adsuara ◽  
Clara Monferrer Adsuara ◽  
Lucía Mata-Moret ◽  
Verónica Castro-Navarro ◽  
Javier Montero-Hernández
Keyword(s):  
Anterior Chamber ◽  
Saline Solution ◽  
Simple Technique ◽  
Fluocinolone Acetonide ◽  
Vitreous Cavity ◽  
Topical Anaesthesia ◽  
Case Presentation ◽  
Fluocinolone Acetonide Implant ◽  
Side Port ◽  
Uncommon Complication

Background: Fluocinolone acetonide implant (ILUVIEN) is a non-biodegradable cylindrical polyimide tube that is injected into the vitreous cavity. Migration to the anterior chamber can potentially occur, especially in patients with posterior capsular defects and vitrectomized eyes, although it is considered an uncommon complication. The best surgical technique is still unknown. We describe a simple technique for reinserting the migrated ILUVIEN implant in the posterior cavity without compromising its integrity. Case Presentation: Under topical anaesthesia, a corneal clear beveled limbal incision is made with a 20G angled side port blade. Balanced saline solution is injected with a 27G anterior chamber cannula to mobilize the implant and a reverse sinskey hook is then used to push the implant to the vitreous cavity between the iris and the intraocular lens without the need of viscoelastic. Conclusion: We report a simple and quick technique for surgical repositioning an ILUVIEN implant that required minimal manipulation and resulted in minimal tissue disturbance without compromising implant integrity and effectiveness. It is important to be cautious while using ILUVIEN in patients with capsular defects, zonular weakness, and previous vitrectomy. We recommend using a reverse sinskey hook as a smaller entry incision can be made to maintain the sealing of the anterior chamber.

Coexistante of intraocular eyelashes and anterior chamber cyst after penetrating eye injury: a case presentation

1994 ◽  
Vol 18 (5) ◽  
pp. 309-311 ◽  
Author(s):  
Süheyla Köse ◽  
Özean Kayikçioglu ◽  
Cezmi Akkin ◽  
Ayşe Yagci ◽  
Gülçin Bašdemir
Keyword(s):  
Anterior Chamber ◽  
Eye Injury ◽  
Case Presentation ◽  
Penetrating Eye Injury

Switching to intravitreal fluocinolone acetonide implant for refractory diabetic macular edema: 12- and 24-month results

2021 ◽  
pp. 112067212199298
Author(s):  
Argyrios Chronopoulos ◽  
Panagiotis Chronopoulos ◽  
Agharza Ashurov ◽  
Christina Korb ◽  
Norbert Pfeiffer ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Fluocinolone Acetonide ◽  
Additional Treatment ◽  
Multicentric Study ◽  
Goldmann Tonometry ◽  
Refractory Diabetic Macular Edema ◽  
Intravitreal Implant ◽  
Fluocinolone Acetonide Implant

Purpose: To report visual and anatomical outcomes of chronic/refractory diabetic macular edema (DME) treated with intravitreal fluocinolone acetonide implant. Setting: Retrospective, one arm, multicentric study. Method: Between 2013 and 2018, 27 consecutive eyes of 25 patients with chronic/refractory DME were treated with a fluocinolone acetonide intravitreal implant. Best registered visual acuity (BRVA), central retinal thickness (CRT), and Goldmann tonometry intraocular pressure (IOP) were assessed at 12 and 24 months. The need for IOP lowering treatment as well as top-up therapy during the follow-up were also assessed. Results: The duration of DME prior to treatment in our study was 54 ± 24 months. The baseline mean BRVA of 0.7 ± 0.34 logMAR improved to 0.5 ± 0.3 ( p = 0.01) at 12 months and 0.46 ± 0.3 ( p = 0.04) at 24 months. At 12 months, BRVA improved in 14 eyes (52%), stabilized in 5 eyes (20%), and decreased in 3 eyes (11%). At 24 months, BRVA improved further in 6 eyes (24%), stabilized in 3 eyes (12%), and decreased in 6 eyes (24 %). Mean CRT decreased from 497 ± 176 to 349 ± 186 μm at 12 months ( p = 0.0005) and to 267 ± 104 μm at 24 months ( p = 0.001). Only five eyes required additional treatment for DME and only three eyes required treatment for raised IOP. Discussion: Our results show that the visual and the anatomical improvements achieved by a single injection of a fluocinolone acetonide implant were maintained up to 24 months with minimal additional therapy even in eyes with a long and heavy history; however, IOP monitoring remains essential.

Late Spontaneous Dissociation of a Fluocinolone Acetonide Implant (Retisert)

2013 ◽  
Vol 21 (1) ◽  
pp. 77-78 ◽  
Author(s):  
Soraya Rofagha ◽  
Tidarat Prechanond ◽  
Jay M. Stewart
Keyword(s):  
Fluocinolone Acetonide ◽  
Fluocinolone Acetonide Implant

Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results

2021 ◽  
pp. 112067212098294
Author(s):  
Ahmed Mohammed Elbarky
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Surgical Intervention ◽  
Previous Treatment ◽  
Fluocinolone Acetonide ◽  
Vascular Endothelial ◽  
Corrected Visual Acuity ◽  
Intravitreal Implant ◽  
Fluocinolone Acetonide Implant ◽  
Endothelial Growth Factors

Introduction: To evaluate 12-month outcomes following fluocinolone acetonide (FAc 0.2 μg/day) implant in pseudophakic patients with diabetic macular edema (DME) that persists or recurs despite previous treatment with anti-vascular endothelial growth factors (anti-VEGF) and dexamethasone implant (DEX) in a UAE population. Methods: A retrospective, observational, single-center, 12-month audit study, where 22 pseudophakic eyes (22 patients) with DME were treated with the FAc intravitreal implant according to licensed UAE indications. Outcome measurements at baseline and at months 1, 3, 6, and 12 included best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP). Results: Post-FAc implantation, mean BCVA significantly improved at 1, 3, and 12 months (+10.4 ± 16.1, +22.8 ± 13.6, and +25.5 ± 13.0 letters, respectively; p < 0.0001), with 86% of eyes gaining ⩾15 letters at month 12. Similarly, CMT reduced significantly at month 1, and stabilized thereafter at months 3–12 (−171.5 ± 72.5 µm, −240.9 ± 74.2 µm, and −246.2 ± 93.4 µm, respectively; p < 0.0001). By month 12, 64% ( n = 14/22) of eyes had a CMT below 300 µm. Only 1 eye had an IOP ⩾ 21 mmHg at baseline and month 12. Five eyes required IOP lowering drops and 1 required IOP-lowering surgical intervention. Conclusion: In pseudophakic patients with DME FAc implant provide a substantial functional and anatomical benefits for up to 12 months.

scholarly journals Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up

2018 ◽  
Vol Volume 12 ◽  
pp. 799-804 ◽  
Author(s):  
Buraa Kubaisi ◽  
Arash Maleki ◽  
Aseef Ahmed ◽  
Neel Lamba ◽  
Haitham Sahawneh ◽  
...  
Keyword(s):  
Fluocinolone Acetonide ◽  
Ahmed Glaucoma Valve ◽  
Fluocinolone Acetonide Implant
Sign in / Sign up

Export Citation Format

Share Document